

SKYEPHARMA PLC
Form 6-K
March 27, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma PLC

SkyePharma to Announce 2005 Full Year Results on 19 April and to Hold Business Review Meeting on 21 June

LONDON, UK, 27 March 2006 - SkyePharma PLC (LSE: SKP, NASDAQ: SKYE) announces today that the Company will host an analyst presentation, which will be webcast live, to be followed by a US

Frank Condella, SkyePharma's Chief Executive Officer, will host the analyst presentation and the interested parties may view the live webcast at 10:00 a.m. (BST) on the Company's website at Relations tab.

US investors and other interested parties may access the conference call at 10:00 a.m. EDT (15:00 US participants and +1-480- 629-9566 for international participants. The slides of the presentation will be available on the Company's website at www.skyepharma.com under the Investor Relations tab.

For those unable to listen to the live broadcast, a replay will be available shortly after the meeting at 1-800-475-6701 for US participants and +1-320-365-3844 for international participants and entering

A Business Review meeting will be held on Wednesday 21 June 2006 at the offices of Buchanan Communications. Attendance is by invitation only but the meeting will be webcast. The meeting will be published nearer the day. This meeting will provide an opportunity to gain an insight into key products in our portfolio and pipeline and to meet members of our senior management team.

For further information please contact:

SkyePharma PLC	+44 207 491 1777
Frank Condella, Chief Executive Officer	
Peter Laing, Director of Corporate Communications	+44 207 491 5124
Sandra Haughton, US Investor Relations	+1 212 753 5780
Buchanan Communications	+44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich	

Notes for editors:

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies and more effective drug formulations. There are now eleven approved and marketed products incorporating the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation technologies. For more information, visit www.skyepharma.com.

Certain statements in this news release are forward-looking statements and are made in reliance upon the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations expressed in these statements are reasonable, it can give no assurance that these expectations will materialize. Because of a number of risks and uncertainties, actual results may vary significantly from those expressed or implied. These risks include, without limitation, risks related to the development of new products, risks related to obtaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to commercialize on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to maintain or expand market share in the face of changes in customer requirements, competition and regulatory compliance, the risk of product liability claims, risks related to the ownership of intellectual property, risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date of this release.

END

SIGNATURES

Edgar Filing: SKYEPHARMA PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: March 27, 2006